LYSA studies presented during 2022 ASCO and EHA Congresses

2 oral communications an 4 posters presented by LYSA in the program of these editions

Discover the different presentations of these 2022 editions

ASCO - American Society of Clinical Oncology

1 poster

FLIRT:

Subcutaneous rituximab induction followed by short rituximab maintenance to improve progression-free survival in patients with low-tumor burden follicular lymphoma: Final results of FLIRT phase III trial, a LYSA study
Guillaume Cartron

EHA - European Hematology Association

2 oral communications

DESCAR-T:

A matched comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory Diffuse Large B-cell Lymphoma: a real-life LYSA study from the French DESCAR-T registry
Emmanuel Bachy

CAR T-cells associated acute toxicity in B-cell Non-Hodgkin Lymphoma: real-world study from the DESCAR-T registry
Pierre Sesques

3 posters

REALYSA:

A large French real world multicentric prospective cohort of patients with lymphoma (REALYSA study):  description of the Diffuse Large B-cell Lymphoma patients in real world in France
Hervé Ghesquières

Intrathecal Methotrexate prophylaxis and Central Nervous System relapse in patients with Diffuse Large B-cell Lymphoma treated with intensified R-ACVBP strategy
Loïc Renaud

FLIRT:

Subcutaneous rituximab induction followed by short rituximab maintenance to improve progression-free survival in patients with low-tumor burden follicular lymphoma: Final results of FLIRT phase III trial, a LYSA study
Guillaume Cartron

Next